Department of Dermatology, Beaumont University Hospital, Dublin, Ireland.
Australas J Dermatol. 2024 May;65(3):276-279. doi: 10.1111/ajd.14292. Epub 2024 Apr 16.
Biologics have significantly advanced the treatment of inflammatory disorders, including psoriasis. However, their use in immunosuppressed patients, such as those with solid-organ transplants, is less understood. These patients often face dermatological issues, but inflammatory skin diseases are rare due to their immunosuppressive treatments. Our study aims to assess biologics' effectiveness in such immunocompromised patients. We report a case from our institution of a 29-year-old man with a history of psoriasis, who underwent a kidney transplant and later developed erythroderma. He did not respond to traditional treatments and was successfully treated with adalimumab, leading to the discontinuation of MMF. We also reviewed literature in solid organ transplant patients with psoriasis. Our findings, based on 10 articles, indicate a cautious approach to using biologics in this group, with further research needed for efficacy and safety.
生物制剂在治疗炎症性疾病方面取得了显著进展，包括银屑病。然而，对于接受实体器官移植等免疫抑制治疗的患者，其应用情况了解较少。这些患者经常面临皮肤问题，但由于免疫抑制治疗，炎症性皮肤病较为罕见。我们的研究旨在评估生物制剂在这些免疫功能低下患者中的疗效。我们报告了一例来自本机构的病例，该患者为 29 岁男性，有银屑病病史，曾接受过肾移植，后来出现红皮病。他对传统治疗方法无反应，接受阿达木单抗治疗后成功缓解，随后停用了霉酚酸酯。我们还对实体器官移植患者中银屑病的文献进行了回顾。我们的研究结果基于 10 篇文章，表明在该人群中使用生物制剂时应谨慎，需要进一步研究其疗效和安全性。
